We recently published 10 Stocks Hit by Painful Plunge. Novo Nordisk A/S (NYSE:NVO) is one of the best-performing stocks on ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

That pundit was HSBC's Rajesh Kumar, who downgraded his recommendation on Novo Nordisk that morning. Image source: . Kumar ...

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...

Novo Nordisk has struggled to adapt to very high demand and a market where celebrities are more influential than doctors.

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

WEIGHT loss jabs could raise the risk of sudden blindness, a study warns. Injections like Wegovy, Mounjaro and Ozempic are ...

Danish leader will face a challenging landscape among competitors ...

Pomerantz LLP is investigating claims on behalf of investors of  Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).  Such investors are advised to contact Danielle Peyton ...